Advances in intensive antihypertensive treatment in hypertensive patients complicated with cardiovascular disease

Abstract

Hypertension is a serious public health problem worldwide and a major risk factor for cardiovascular disease. Hypertensive patients are constantly complicated with cardiovascular disease. Effective blood pressure control could improve clinical prognosis of these patients. In June 2023， 2023 ESH Guidelines for the management of arterial hypertension were released with updated recommendations for the timing of starting antihypertensive therapy. For patients with normal high-value blood pressure with prior cardiovascular disease， the guidelines recommend initiating antihypertensive therapy from 130/80 mmHg. The 2023 edition of the Chinese Guidelines for the Prevention and Control of Hypertension also recommends that the target blood pressure for those with high and very high cardiovascular risk can be further reduced to less than 130/80 mmHg. This suggests that greater clinical benefit can be achieved from intensive blood pressure control in hypertensive patients with comorbid cardiovascular disease. In recent years， multiple studies have shown the advantages of intensive blood pressure management in hypertensive patients. In this article， the progress in clinical studies related to intensive blood pressure control in hypertensive populations complicated with different cardiovascular diseases was reviewed， aiming to provide insight and evidence for intensive antihypertensive treatment in these patients.

Keywords

• hypertension|intensive antihypertensive treatment|coronary heart disease|heart failure|atrial fibrillation